相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
招募中
6
100.0%
暂无批准数据
- At 20 years, IM-MS irradiation reduced breast cancer mortality to 10.0% versus 14.2% in the control group (HR 0.70, p=0.010) in node-negative breast cancer patients. - Overall survival was nearly identical between groups at 69.0% vs 68.4% (HR 0.98, p=0.77), with no long-term survival advantage from regional nodal irradiation. - Non-breast cancer mortality was higher in the IM-MS group after 15 years, reaching 20.9% vs 17.4% at 20 years (HR 1.24, p=0.048). - The findings underscore the importance of individualized patient selection, modern organ-sparing radiation techniques, and very long-term follow-up in early breast cancer.
- Bavarian Nordic has launched two groundbreaking clinical trials to evaluate the safety and immunogenicity of MVA-BN mpox vaccine in 344 infants aged 4-24 months and 359 pregnant or breastfeeding women. - Both studies are being conducted in the Democratic Republic of Congo, the epicenter of the ongoing mpox outbreak, where these vulnerable populations remain at high risk. - The trials are part of the PregInPoxVac research project and could support regulatory approval to expand MVA-BN vaccine access to the most vulnerable populations. - Results from a concurrent pediatric trial in children aged 2-11 years are expected in Q3 2025, potentially supporting broader age group approvals.
- New research presented at the European Congress of Psychiatry suggests cannabidiol (CBD) extract improves social responsiveness and reduces disruptive behavior in children with autism spectrum disorder. - The meta-analysis of three clinical trials involving 276 participants showed CBD helped ease anxiety and potentially improved sleep quality, with researchers noting a favorable safety profile compared to placebo. - Despite promising results, lead researcher Dr. Lara Branco emphasizes the need for larger clinical trials to fully establish efficacy and safety before CBD can be recommended as a standard autism treatment.
